why choose us

Course: Navigating Resistance, Relapse, and Treatment Sequencing in Relapsed/Refractory CLL

CME Credits: 0.50

Released: 2025-12-19

Recent insights into chronic lymphocytic leukemia (CLL) have shed light on how resistance emerges following targeted therapies, revealing new complexities in the management of relapsed or refractory disease. As treatment options expand, clinicians—particularly those serving rural and underserved communities—face increasing challenges in determining optimal sequencing strategies, identifying appropriate combination approaches, and safely managing adverse events. This online, on-demand CME/CE activity—part of the series Keeping Up With the Evolving Landscape of CLL: Practical Solutions for Reducing Disparities in Rural and Underserved Communities—will examine mechanisms of resistance and relapse after first-line therapy, practical considerations for sequencing and combination treatment in relapsed/refractory CLL, and strategies to support safe, effective care delivery in community oncology settings. Expert faculty will also highlight emerging therapeutic targets and new data that may further refine the CLL treatment landscape. The content for this enduring activity was recorded on December 12, 2025.


Upon completion of this activity, participants should be better able to:


View Full Course